Cargando…
Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
Histone deacetylase inhibitors (HDACIs) are novel anticancer agents with potent cytotoxicity against a wide range of malignancies. We have previously demonstrated that either Calphostin C (CC) (a protein kinase C (PKC) inhibitor) or Parthenolide (an NF-κB inhibitor) abrogates HDACI-induced transcrip...
Autores principales: | Yeow, W-S, Ziauddin, M F, Maxhimer, J B, Shamimi-Noori, S, Baras, A, Chua, A, Schrump, D S, Nguyen, D M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361280/ https://www.ncbi.nlm.nih.gov/pubmed/16705314 http://dx.doi.org/10.1038/sj.bjc.6603132 |
Ejemplares similares
-
Abrogation of the radiation-induced G2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines
por: Playle, L C, et al.
Publicado: (2002) -
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
por: Blaheta, R A, et al.
Publicado: (2007) -
p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014) -
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
por: Atmaca, A, et al.
Publicado: (2007) -
Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)